Brief: Vaccitech To Present Final Data At EASL Congress For Phase 1B/2 HBV002 Study
21/06/2023 22:49
June 21 (Reuters) - Vaccitech PLC VACC.O :
* VACCITECH TO PRESENT POSITIVE FINAL DATA AT EASL CONGRESS
FOR
PHASE 1B/2 HBV002 STUDY IN ADULTS WITH CHRONIC HEPATITIS B
Source: (https://shorturl.at/bcANW)
Further company coverage: VACC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing